Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360º synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence and prevalence of migraine
3.2.1.2 Rising patient preference for non-invasive treatment
3.2.1.3 Growing awareness and diagnosis of migraine
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements
3.2.2.2 Competition from alternative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Pricing analysis
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Million)
5.1 Key trends
5.2 Pain relieving medication
5.2.1 Triptans
5.2.2 Analgesics
5.2.3 Ditans
5.2.4 Other pain-relieving medications
5.3 Prescription medication
5.3.1 Anticonvulsant
5.3.2 Antidepressant
5.3.3 Beta blocker
5.3.4 CGRP inhibitors
5.3.5 Other preventive medications
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)
6.1 Key trends
6.2 Oral
6.3 Injectable
6.4 Nasal
6.5 Transdermal
Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)
7.1 Key trends
7.2 Prescription drugs
7.3 OTC drugs
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Drug store & retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Amgen, Inc.
10.3 Astellas Pharma
10.4 AstraZeneca Plc
10.5 Azurity Pharmaceutical, Inc.
10.6 Dr. Reddy’s Laboratories, Inc.
10.7 Eli Lilly and Company
10.8 Endo Pharmaceuticals, Inc.
10.9 GlaxoSmithKline Plc
10.10 Lannett Company, Inc.
10.11 Lundbeck A/S
10.12 Pfizer, Inc.
10.13 Sanofi SA
10.14 Sun Pharmaceutical Industries Limited
10.15 Teva Pharmaceutical Industries Limited
